Abstract
Background The cytokine interleukin-2 (IL-2) can stimulate both effector immune cells and regulatory T (Treg) cells. The ability of selectively engaging either of these effects has spurred interest in using IL-2 for immunotherapy of cancer and autoimmune diseases. Thus, numerous IL-2-based biologic agents with improved bias or delivery toward effector immune cells or Treg cells have been developed. These improved IL-2-based compounds recently entered clinical trials.
Objective This study systematically reviews clinical results of improved IL-2-based compounds for the treatment of cancer or autoimmune diseases.
Methods We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), searched the ClinicalTrials.gov database for registered IL-2 trials using improved IL-2-based agents and different databases for available results of these studies.
Results We identified 547 registered clinical trials, of which we extracted 36 studies on improved IL-2-based compounds. Moreover, we assessed another 9 agents reported in two recent literature reviews and based on our knowledge, totaling in 45 improved IL-2-based compounds. A secondary search for registered clinical trials of each of these improved 45 compounds resulted in 139 clinical trials included in this systematic review, with 29 trials reporting clinical results.
Conclusions As of yet, none of the improved IL-2-based compounds gained regulatory approval for the treatment of cancer or autoimmune diseases. Three compounds treating cancer have entered phase 3 trials with two studies still ongoing. NKTR-214 is the only compound that has completed phase 3 studies. The PIVOT IO-001 study testing the combination of NKTR-214 plus Pembrolizumab compared to Pembrolizumab monotherapy in metastatic melanoma missed its primary endpoint of superior objective response rate and progression-free survival. The PIVOT-09 study, combining NKTR-214 with Nivolumab compared to Sunitinib or Cabozantinib in advanced renal cell carcinoma, missed its primary endpoint of improved objective response rate. Trials in autoimmune diseases are currently in early stages, thus not allowing conclusions on efficacy. Results of ongoing trials will provide insight into which improved IL-2-based compounds will be beneficial for cancer and autoimmune diseases.
Competing Interest Statement
MR, UK, and OB hold patents on improved IL-2-based compounds and OB is a shareholder of Anaveon. MR discloses paid consulting activities for Urogen. DS states no competing interests related to this work.
Funding Statement
This work was supported by the Swiss National Science Foundation (310030-172978 and 310030-200669; to O.B.), Hochspezialisierte Medizin Schwerpunkt Immunologie (HSM-2-Immunologie; to O.B.), the Clinical Research Priority Program CYTIMM-Z of University of Zurich (to O.B.), a Young Talents in Clinical Research Fellowship and a Project Grant by the Swiss Academy of Medical Sciences and G. & J. Bangerter-Rhyner Foundation (YTCR 32/18 and YTCR 08/20; to M.R.), and a Filling-the-Gap Fellowship by University of Zurich (to M.R.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study reports clinical results from multiple clinical trials. The results of all these trials were publicly available, either as peer-reviewed publications, meeting abstracts, press releases or on ClinicalTrials.gov. All synthesized results reported are referenced in the article.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The full dataset generated for this study is available upon request from the corresponding authors upon publication of this manuscript in a peer-reviewed journal.
